ArticleJournal of orthopaedic case reports2025
Role of Ortho Biologics in Subtrochanteric Osteotomy Non-union in a Case of Developmental Hip Dysplasia Managed with Total Hip Replacement - A Case Report.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hip dislocations are very common at a younger age because of predisposing factors, such as laxity of the hip. If not reduced promptly, osteonecrosis of the femoral head can occur, requiring osteotomies or hip replacement later in life. In case of severe deformities, along with hip replacement, subtrochanteric osteotomy is often needed so as to address deformity and limb length discrepancy. Non-unions at the osteotomy site are not rare and can be treated with orthobiologics. Orthobiologics have been found to increase union rates, decrease healing times, and enhance union in long bone fractures. Plateletrich plasma (PRP) and bone marrow aspirate concentrate (BMAC) are rich sources of several growth factors that promote angiogenesis and osteogenesis through multiple mechanisms. Case Report: Here, we discuss the case of a 27-year-old male who had congenital hip dislocation, which was managed conservatively. At 18 years of age, he underwent a pelvic osteotomy and limb lengthening procedure. The symptoms subsided, but there was a recurrence of pain for the past 2 years, which was aggravated with movements. He was diagnosed with Crowe type IV dysplastic hip, and a right total hip with long stem was carried out along with subtrochanteric osteotomy. However, at 3 months of follow-up, the union was not sufficiently appreciated on radiograph, and the patient still complained of pain. Conclusion: Hence, a single dose of BMAC injection was given, followed by three doses of PRP injections. The final follow-up was done 1 year after the surgery, and the patient had satisfactory outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.